P
Description
Promore Pharma is a Swedish clinical-stage biopharmaceutical company based in Solna, specializing in developing therapeutic peptides for the advanced wound care market. Its lead candidate ropocamptide (LL-37) showed positive Phase IIb results for venous leg ulcers (75% wound area reduction at one month). Second candidate ensereptide (PXL01) targets post-surgical scar prevention. Holds a European patent for the use of ropocamptide in chronic wounds.